Zelira Therapeutics (ZLD) AI Stock Analysis

• Market Cap: AU$7.38M
• Dividend Yield: N/A
• Average Volume (3M): 1.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.47
• Revenue Growth: -99.31%
• EPS Growth: 90.20%
• Country: AU
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.10
• Shares Outstanding: 11,897,155
• 10 Day Avg. Volume: 1,056
• 30 Day Avg. Volume: 1,924
• PEG Ratio: 0.02
• Price to Book (P/B): -1.13
• Price to Sales (P/S): 7702.11
• P/FCF Ratio: -1.03
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: AU$0.70 ▲(106.18% Upside)

The score is held down primarily by very weak financial performance (sharp revenue collapse, negative margins, negative equity, and negative operating/free cash flow). Technicals provide partial support due to strong momentum and price above key moving averages, but overbought RSI increases downside risk. Valuation offers limited support because earnings are negative and no dividend yield is available.

Positive Factors

Proprietary formulations & clinical research

Proprietary cannabinoid formulations and an emphasis on clinical research create durable product differentiation and intellectual property. Over the medium term this supports regulatory credibility, prescriber and payer acceptance, and higher switching costs versus commoditized alternatives.

Diverse revenue model (sales, partnerships, royalties)

A business model combining product sales with partnership agreements, milestone payments and royalties provides structural revenue diversification. This reduces reliance on a single channel, can supply non-dilutive funding for R&D, and enables market expansion via partners over months.

Signs of free cash flow improvement

A reported uptick in free cash flow growth and FCF-to-net-income parity (albeit from negative base) indicates early operational stabilization. If sustained, modest FCF recovery would extend runway, reduce dependence on external financing, and allow targeted reinvestment in commercialization or trials.

Negative Factors

Severe revenue collapse

A nearly 100% revenue decline is a structural red flag: loss of scale weakens gross margin prospects, reduces ability to cover fixed costs, and limits funds for R&D and commercialization. Without durable revenue recovery, the business model and market position are materially impaired.

Negative shareholders' equity

Negative equity indicates balance sheet insolvency risk and constrains financing options. This structural weakness limits access to traditional debt, raises likelihood of covenant breaches or distressed financings, and often necessitates dilutive capital raises that harm long-term shareholder value.

Persistent negative operating and free cash flows

Sustained negative operating and free cash flows signal a cash-burning profile that requires continual external funding. Over months this reduces strategic flexibility, heightens dilution risk, and can force delays or cuts to clinical and commercial initiatives critical for long-term value creation.

Zelira Therapeutics Business Overview & Revenue Model

Company Description

Zelira Therapeutics (ZLD) is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid-based therapeutics. Operating primarily in the healthcare sector, Zelira aims to address various health conditions, including chronic pain, sleep disorders, and other serious ailments. The company leverages its proprietary formulations and clinical research to create products that are designed to improve patient outcomes and quality of life.

How the Company Makes Money

Zelira Therapeutics generates revenue primarily through the sale of its proprietary cannabinoid-based products, which are marketed to both consumers and healthcare providers. The company also engages in partnerships and collaborations with other pharmaceutical companies and research institutions to develop new therapies and expand its product portfolio. Additionally, Zelira may receive funding through grants, licensing agreements, and joint ventures that support its research and development efforts. These strategic partnerships often include milestone payments and royalties, further contributing to the company's earnings.

Zelira Therapeutics Financial Statement Overview

Summary

Very weak fundamentals: revenue fell sharply (-98.4%), margins are negative (gross, EBIT, and net), the balance sheet shows negative stockholders’ equity, and both operating and free cash flow are negative—indicating significant financial instability and ongoing cash burn.

Income Statement

Zelira Therapeutics has experienced significant revenue decline, with a revenue growth rate of -98.4% in the most recent year. The company has negative gross profit, net profit, and EBIT margins, indicating substantial losses. These metrics reflect severe financial challenges and a lack of profitability.

Balance Sheet

The balance sheet shows negative stockholders' equity, which is concerning. The debt-to-equity ratio is negative due to negative equity, and the return on equity is positive but misleading due to negative equity. The equity ratio is also negative, indicating financial instability.

Cash Flow

The company has negative operating and free cash flows, with a slight improvement in free cash flow growth. However, the operating cash flow to net income ratio is negative, reflecting ongoing cash flow challenges. The free cash flow to net income ratio is 1.0, indicating that all net income is being used for free cash flow, but this is due to both being negative.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	655.00	656.00	94.95K	301.12K	1.54M	663.32K
Gross Profit	-802.95K	-802.95K	10.28K	-3.22M	-5.72M	-39.16K
EBITDA	-4.17M	-4.17M	-36.44M	-6.79M	-13.06M	-9.41M
Net Income	-3.63M	-3.63M	-36.57M	-5.57M	-11.95M	-8.55M
Balance Sheet
Total Assets	1.30M	1.30M	5.18M	33.89M	37.70M	39.37M
Cash, Cash Equivalents and Short-Term Investments	5.66K	5.66K	586.16K	146.21K	2.75M	4.97M
Total Debt	2.14M	2.14M	5.95M	437.90K	500.91K	551.08K
Total Liabilities	5.59M	5.59M	9.36M	2.18M	2.01M	1.54M
Stockholders Equity	-4.46M	-4.46M	-4.51M	31.80M	35.20M	37.83M
Cash Flow
Free Cash Flow	-4.91M	-4.91M	-4.39M	-7.25M	-9.43M	-8.62M
Operating Cash Flow	-4.91M	-4.91M	-4.39M	-7.25M	-9.43M	-8.62M
Investing Cash Flow	1.15M	1.15M	919.74K	2.83M	-207.78K	1.38M
Financing Cash Flow	3.19M	3.19M	3.92M	1.77M	7.10M	10.53M

Zelira Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.34
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ZLD, the sentiment is Positive. The current price of 0.34 is below the 20-day moving average (MA) of 0.59, below the 50-day MA of 0.46, and below the 200-day MA of 0.42, indicating a bullish trend. The MACD of 0.06 indicates Positive momentum. The RSI at 54.75 is Neutral, neither overbought nor oversold. The STOCH value of 10.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ZLD.

Zelira Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ZLD	49 Neutral	AU$7.38M	-1.96	―	―	-99.31%	90.20%
NSB	49 Neutral	AU$46.56M	-11.11	-16.65%	―	―	-672.73%
IXC	48 Neutral	AU$9.39M	-19.84	-8.72%	―	―	71.10%
CMB	48 Neutral	AU$13.78M	-2.29	-166.70%	―	―	―
AVE	44 Neutral	AU$33.06M	-9.09	-143.71%	―	306.88%	―
1AD	37 Underperform	AU$11.47M	-1.61	-628.72%	―	―	31.87%

Zelira Therapeutics Corporate Events

Zelira Secures US$33m Strategic Investment to Advance HOPE® 1 Autism Therapy

Zelira Therapeutics has secured binding agreements with TGC Biotechnology Fund (ThirdGate Capital) for a US$32.98 million equity investment into its HOPE® 1 special purpose vehicle, valuing the SPV at about US$66 million and Zelira’s post-money stake at roughly US$26.19 million. The deal will leave ThirdGate holding 50% of the HOPE® 1 SPV on a fully diluted basis, with Zelira retaining 39.7%, and is expected to fully fund an accelerated U.S. development program via the FDA’s 505(b)(2) pathway for HOPE® 1 in Phelan-McDermid Syndrome co-morbid with autism, a rare, genetically defined subset of autism spectrum disorder that may qualify for orphan drug designation. The funding underscores investor confidence in HOPE® 1’s clinical and commercial potential, strengthens Zelira’s balance sheet exposure to a key asset, and positions the company to advance first-in-human trials in the United States, with potential long-term benefits from exclusivity and regulatory incentives if orphan status is granted.

The most recent analyst rating on (AU:ZLD) stock is a Sell with a A$0.33 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.

Zelira Therapeutics Adjusts Director’s Interest with Convertible Notes

Zelira Therapeutics announced a change in the interest of its director, Oludare Odumosu, involving the acquisition of 386,847 convertible notes. This change reflects the issuance of convertible notes to replace a Convertible Loan Agreement, which was approved by shareholders, potentially impacting the company’s financial structure and signaling strategic financial adjustments.

The most recent analyst rating on (AU:ZLD) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.

Zelira Therapeutics Issues Unquoted Convertible Notes

Zelira Therapeutics Limited announced the issuance of 580,270 unquoted convertible notes as part of a previously announced transaction. This move is part of the company’s strategic financial management, potentially impacting its capital structure and providing additional resources for its ongoing projects and market expansion efforts.

The most recent analyst rating on (AU:ZLD) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.

Zelira Therapeutics Secures $1.07 Million R&D Tax Refund

Zelira Therapeutics has received a $1,070,000 cash refund from the Australian Federal Government’s R&D Tax Incentive Scheme. This refund will support the company’s ongoing clinical and product development programs, as well as initiatives for pipeline products and essential business operations, thereby strengthening its position in the cannabis medicine industry.

The most recent analyst rating on (AU:ZLD) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.

Zelira Therapeutics Announces Proposed Securities Issue

Zelira Therapeutics Limited has announced a proposed issue of securities, specifically a convertible note, with a maximum of 580,271 securities to be issued. This move is part of their strategy to raise capital, potentially impacting the company’s financial position and market operations as they continue to expand their offerings in the cannabinoid-based medicine sector.

The most recent analyst rating on (AU:ZLD) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.

Zelira Therapeutics Focuses on Operational Scale in 2025

Zelira Therapeutics’ 2025 Annual General Meeting highlighted the company’s focus on validating its operational scale. The announcement underscores Zelira’s strategic intentions and future plans, acknowledging the inherent risks and uncertainties in achieving these objectives. The company’s efforts to expand its operational capabilities are crucial for its positioning in the cannabinoid therapeutics industry, with potential implications for stakeholders as it navigates market challenges.

The most recent analyst rating on (AU:ZLD) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.

Zelira Therapeutics Secures R&D Loan and Advances Clinical Trials

Zelira Therapeutics has announced a non-dilutive R&D loan facility secured against its anticipated R&D tax incentive rebate for FY25, which will be used to advance the HOPE® SPV clinical trial and general working capital. Additionally, the company’s directors have provided unsecured loan notes to support operations. The company is making significant progress in its FDA program for the HOPE® clinical trial, with plans to launch Phase 1 trials for its HOPE® 1 Phelan McDermid Syndrome program. This development is part of Zelira’s strategy to bring effective cannabinoid-based therapies to market, targeting ultra-rare genetic conditions and improving patient outcomes.

The most recent analyst rating on (AU:ZLD) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.

Zelira Therapeutics Announces Cessation of Securities

Zelira Therapeutics Limited announced the cessation of 125,723 securities due to the expiry of options or other convertible securities without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions and market positioning as the company continues its strategic initiatives.

The most recent analyst rating on (AU:ZLD) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Zelira Therapeutics stock, see the AU:ZLD Stock Forecast page.